Biovie Inc. (BIVI): Operating Cash Flow
-$19.02M
Year ended 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | -$19.02M | n/m | 2026-08-13, From 2025-07-01 |
| 2025-06-30 | -$19.03M | n/m | 2026-08-13, From 2024-07-01 |
| 2024-06-30 | -$27.95M | n/m | 2025-08-15, From 2023-07-01 |
| 2023-06-30 | -$40.25M | n/m | 2024-09-30, From 2022-07-01 |
| 2022-06-30 | -$18.99M | n/m | 2023-08-16, From 2021-07-01 |
| 2021-06-30 | -$10.45M | n/m | 2022-09-27, From 2020-07-01 |
| 2020-06-30 | -$1.63M | n/m | 2021-08-30, From 2019-07-01 |
| 2019-06-30 | -$2.50M | n/m | 2020-08-07, From 2018-07-01 |
| 2018-06-30 | -$621.3K | n/m | 2019-09-27, From 2017-07-01 |
| 2017-06-30 | -$623.6K | n/m | 2018-10-05, From 2016-07-01 |
| 2016-06-30 | -$153.6K | n/c | 2017-08-24, From 2015-07-01 |
| 2015-06-30 | -$65.4K | n/m | 2016-09-28, From 2014-07-01 |
| 2014-06-30 | -$172.8K | n/m | 2015-10-01, From 2013-07-01 |
| 2013-06-30 | -$2.5K | n/a | 2014-09-24, From 2012-07-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Biovie Inc. (BIVI) | 2026-06-30 | -$19.02M | n/m |
| Exicure, Inc. (XCUR) | 2025-12-31 | -$8.55M | n/m |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | -$19.21M | n/m |
| CytoDyn Inc. (CYDY) | 2026-05-31 | -$17.25M | n/m |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | -$11.13M | n/m |
| CalciMedica, Inc. (CALC) | 2025-12-31 | -$21.18M | n/m |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | -$23.12M | n/m |
| Edesa Biotech, Inc. (EDSA) | 2025-09-30 | -$7.32M | n/m |
| Cingulate Inc. (CING) | 2025-12-31 | -$17.25M | n/m |
Compare BIVI, XCUR, ACTU, CYDY side by side · Screen every company in Pharmaceutical Preparations ↗